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Abstract
The cell therapy industry has grown rapidly over the past 3 decades, and multiple clinical trials have been performed to
date covering a wide range of diseases. The most frequently used cell is mesenchymal stromal cells (MSCs), which have
been used largely for their anti-inflammatory actions and in situations of tissue repair and although they have demon-
strated a good safety profile, their therapeutic efficacy has been limited. In addition to these characteristics MSCs are being
used for their homing and engraftment properties and have been genetically modified to enable targeted delivery of a variety
of therapeutic agents in both malignant and nonmalignant conditions. This review discusses the science and technology
behind genetically modified MSC therapy in malignant disease and how potential problems have been overcome to enable
their use in two novel clinical trials in metastatic gastrointestinal and lung cancer.
Introduction
The landscape of cellular therapies has changed dra-
matically over the past 20 years and is likely to continue
to do so over the next decade.There is an increasing
drive to overcome existing roadblocks to large-scale
use to provide a more streamlined route to market.
The value of the cell therapy industry is projected to
reach £20 billion by 2022, and the array of cell thera-
pies being investigated is rapidly expanding [1].There
are currently more than 500 clinical trials using mes-
enchymal stromal cells (MSCs) registered on the
National Institutes of Health clinical trials database
and an increasing proportion of these are using ge-
netically modified MSCs (http://www.clinicaltrials.gov;
accessed August 2016). In the United Kingdom alone
37% of trials use genetically modified cells, the ma-
jority of which use viral vectors for gene delivery [2].
The term “cell therapy” covers a wide array of
products, and they are most commonly classified ac-
cording to cell type (e.g., hematopoietic stem cells,
MSCs, embryonic stem cells, modifiedT cells).Within
these cell types, the range of diseases being treated are
vast, ranging from immunomodulation to target in-
flammatory diseases such as inflammatory bowel
disease [3], chronic obstructive pulmonary disease [4]
and acute lung injury [5,6] to acute stroke [7,8], acute
myocardial infarction [9,10], and graft-versus-host
disease [11]. Stem cells are also being used for tissue
repair and regeneration with differentiation being
directed to the target organs such as bone and carti-
lage [12].There is also increasing interest in the use
of genetically modified cell therapies including chi-
meric antigen receptor (CAR) T cells and cells
genetically modified to express therapeutic proteins
targeted to a specific disease.
Within this review we discuss the use of geneti-
cally modified MSCs as a therapy for cancer and in
particular discuss our own experience of developing
and cell and gene therapy product for the treatment
of metastatic lung cancer to be delivered in a phase
I/IIa clinical trial.
MSCs
MSCs were first described in the 1970s by Friedenstein
et al. [13] and are now one of the most widely
characterised adult stem cells. As determined by the
International Society for CellularTherapy (ISCT), they
must meet the minimum criteria of being adherent
to tissue culture plastic under standard culture con-
ditions, express the cell surface markers CD105, CD73
and CD90 and lack expression of CD45, CD34, CD14
or CD11b, CD79α or CD19 and HLA-DR surface
molecules. In addition, they must be capable of dif-
ferentiating into adipocytes, osteoblasts and
chondroblasts under the correct experimental condi-
tions [14]. MSCs are a heterogeneous population of
cells, and their characteristics are affected by passage,
cell density and culture conditions [15]. They are
Correspondence: Sam M. Janes, MBBS, PhD, FRCP, Lungs for Living Research Centre, UCL Respiratory, Division of Medicine, Rayne Building, 5 University
Street,WC1E 6JF London, United Kingdom. E-mail: s.janes@ucl.ac.uk
(Received 11 August 2016; accepted 2 September 2016)
ISSN 1465-3249 Copyright © 2016 The Authors. Published by Elsevier Inc. on behalf of International Society for Cellular Therapy. This is an open access
article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
http://dx.doi.org/10.1016/j.jcyt.2016.09.003
Cytotherapy, 2016; 18: 1435–1445
readily available from multiple sources, including bone
marrow [16], adipose tissue [17] and umbilical cord
[18], among others, and although cells from all sources
will meet the minimum criteria for MSC definition,
there are subtle differences in their behavior that further
complicates our understanding of this cell type.These
differences may be therapeutically beneficial in some
cases in terms of either their secretory profile or growth
characteristics, but as yet there are no data that di-
rectly compare the core characteristics of the different
sources of MSCs, and the ideal cell source is likely
to be dependent on the indication for its use.
MSCs can be easily extracted from adults and ex-
panded in vitro and, once isolated, have a number of
characteristics that make them appealing vectors for
delivery of therapeutic agents. One of the key prop-
erties of MSCs is their tumor tropism, that is, their
propensity to move toward sites of tumor [19,20].The
precise mechanism through which this process occurs
is unknown, but it has been demonstrated in multi-
ple cancer models including glioma [21,22], breast
carcinoma [23], lung cancer [24,25], malignant me-
sothelioma [26], hepatocellular carcinoma [27,28],
colon cancer [29], pancreatic cancer [30,31], ovarian
cancer [32], melanoma [33] and Kaposi sarcoma [34].
The tropism is thought to be mediated through
paracrine signaling between the tumor microenviron-
ment and corresponding receptor expression in MSCs.
Although tumor tropism has been consistently dem-
onstrated, the precise mechanisms responsible remain
poorly understood. Many factors have been assessed
with regards to this property including multiple re-
ceptors, extracellular matrix proteins, tumor necrosis
factor α (TNFα), interleukins (ILs), macrophage mi-
gration inhibitory factor (MIF) and, most frequently,
the soluble tumor–derived factor stromal-derived factor
(SDF)-1 [35–37]. The most widely studied interac-
tion has been that between SDF-1 and CXCR4, but
the involvement of this axis remains controversial [38].
Another characteristic of MSCs that make them at-
tractive for therapeutic use is their low immunogenic
state in that they elicit a weak allogeneic immune re-
sponse when delivered to a non-identical, non-matched
recipient [39,40].These unique properties are attrib-
uted to the low levels of expression of major
histocompatibility complex (MHC) class I and the co-
stimulatory molecules CD80 and CD86 and the lack
of MHC class II proteins [41–44]. Because of these
properties, there is the potential for using allogeneic
MSCs as an “off-the-shelf” product.To use cells from
healthy, young donors that are likely to have greater re-
generative capacities and higher proliferative rates would
be an attractive option to help control the costs and
complexity of the manufacturing process, which would
be a significant factor in the long-term likelihood of
making cell therapies commercially viable. Although
there is evidence that the source of MSCs and their
culture conditions can alter their immunomodulatory
properties, there is no direct comparison of the immune
profile of cells from different sources or after culture
in different conditions [45,46].
Genetic modification
Going hand in hand with their tumor tropism is the
ability of MSCs to be modified to allow sustained de-
livery of specific anti-cancer agents. Because the cells
are attracted to tumor stroma, targeted therapeutic de-
livery can be achieved at multiple tumor sites.There
are many methods to genetically modify MSCs, but
they can be broadly classified into viral and non-
viral methods. A detailed discussion of methods of
modification andMSC engineering is outside the scope
of this review; however, excellent overviews of this are
provided by Park et al. [47] and others [48,49].
Non-viral vectors
Non-viral methods of gene transfer encompass all phys-
ical and chemical methods of gene delivery. These
methods are appealing because they are able to deliver
larger transgenes than viral methods, are more cost-
effective and are amenable to scale-up manufacturing
and induce less of an immune response. Despite these
benefits, there are a number of limitations, the main
one being their low transfection efficiencies and tran-
sient gene expression [47]. Physical methods of gene
delivery are based on temporarily penetrating the cell
membrane using techniques such as electroporation
[50–53], ultrasound [54,55], magentofection [56] and
DNA particle bombardment by gene gun [57,58].
Chemical methods tend to use cationic lipids or poly-
mers, which form negatively charged particles that are
taken up into the cell by endocytosis, but these methods
are largely limited to in vitro use [59,60]. Cell surface
receptors have been explored, and other non-viral
methods of modification being investigated are via li-
posomes [61] or nanoparticles [62].
Viral vectors
Viral transduction of MSCs is commonly achieved
using lenti-, retro-, adeno- or adeno-associated virus
without affecting their stem cell properties [63,64].
Viral vectors use the innate ability of the virus to gain
entry into and survive within the host cell nucleus to
ensure continued expression of the viral genome.To
make them useful as delivery vectors, they have un-
dergone significant modification to produce replication
incompetent viruses with attenuated cytopathic effects
and immunogenicity. One of the enduring concerns
regarding the use of viral vectors is their safety, but
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advances in vector design have helped to alleviate this
matter [65–69].
Each type of viral vector has its pros and cons
(Table I), and the choice of vector used will be de-
pendent on the therapy required and the disease being
treated.Viral vectors are particularly appealing because
they enable high transduction efficiency and, depend-
ing on the type of virus used, can deliver long-term
stable transgene expression.The choice of genetic mod-
ification will be determined by the aim of the therapy.
Some genetic modification is designed to improve
homing by overexpression of key chemokines such as
CXCR4 [70] and epidermal growth factor receptor
[71], and others aim to deliver a specific therapeutic
protein, such as the pro-apoptotic molecule TNF-
related apoptosis inducing ligand (TRAIL) [25,26,72].
Other modifications being assessed for therapeutic ef-
ficacy in a variety of pre-clinical disease models include
interferon (IFN)-β (IFNβ) [21,33,73,74], IL-12
[75,76], IFN-ɣ [77], angiopoietin 1 [78], endothe-
lial nitric oxide synthase [79] and vascular endothelial
growth factor (VEGF) [80].
Genetically engineered MSCs as cancer
therapeutics
Cancer is a devastating disease, and the number of
people diagnosed every year is on the increase. Fifty
percent of people born after 1960 are likely to be di-
agnosed with some form of cancer during their lifetime,
and breast, prostate, lung, and bowel cancers were re-
sponsible for more than 50% of the cancer diagnoses
in the United Kingdom in 2013. For all cancers, the
10-year survival rate is 50%, but this is highly vari-
able depending on the specific cancer subtype. Lung
cancer has a particularly poor prognosis with an in-
cidence of >45 000 in the United Kingdom alone in
2013 and more than 35 000 deaths. The 10-year
survival is only 10%, a figure that has not changed
significantly over the past 40 years. Breast cancer, on
the other hand, fares much better with >53 000 new
diagnoses a year with a 78% 10-year survival; that of
prostate cancer is even better with an 84% 10-year
survival rate [81].
Regardless of the type of cancer, there are three
main categories of treatment: surgery, chemotherapy
and radiotherapy. Surgery is often the only curative
treatment, but many patients will have to undergo either
chemotherapy, radiotherapy or both in addition to
surgery. For those in whom surgery is not an option,
the mainstay of treatment is usually chemotherapy, par-
ticularly for those with advanced disseminated disease.
The main problem with existing chemotherapy agents
is their toxicity, with the most common side effects
being marked gastrointestinal upset, such as nausea
and vomiting, and bone marrow suppression making
patients susceptible to overwhelming infection and in
some cases death.
With the significant side effect profile of tradition-
al chemotherapeutics, novel cancer treatments are
needed and a number of groups are looking to cap-
italize on the tumor tropic properties of MSCs to
develop targeted anti-cancer therapies using MSCs as
delivery vehicles.
Pre-clinical therapies
A number of pre-clinical studies have looked at the
efficacy of genetically engineeredMSCs in a wide range
of malignant diseases. These have used MSCs from
a variety of sources, different transfection methods for
gene delivery, multiple different transfected prod-
ucts and a wide range of tumor models, but despite
these variations, the data have consistently shown a
reduction in tumor growth and prolonged survival
(Table II).
Table I. Summary of viral vectors used in gene therapy.
Viral vector Structure Advantages Disadvantages
Adenovirus Double-stranded DNA DNA incorporated into host cell nucleus
Infects dividing and quiescent cells
Transient gene expression
Lower risk of genotoxicity
Large DNA inserts
Transient gene expression
Immunogenic
Insertional mutagenesis
Adeno-associated virus (AAV) Single-stranded DNA Infects dividing and quiescent cells
Long-term gene expression
Non-cytotoxic
Non-immunogenic
Small DNA inserts
Retrovirus Single-stranded RNA DNA incorporated into host cell genome
Long-term stable gene expression
Insertional mutagenesis
Oncogene activation
Lentivirus Single-stranded RNA DNA incorporated into host cell genome
Long-term stable gene expression
Infects dividing and quiescent cells
Replication incompetent
No insertion into oncogene
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One of the first studies exploring the use of ge-
netically modified MSCs in cancer transduced human
MSCs with INF-β and injected them to treat a murine
xenograft model of melanoma, resulting in a reduc-
tion in tumor growth and increased survival in treated
animals [33]. This approach has subsequently been
used in models of breast cancer and glioma with similar
beneficial effects [21,73]. Following from this, other
groups have looked at developing therapeutics aimed
at targeting cell proliferation using IL-12 [82], an-
giogenesis with VEGFR-1 [83] and pigment
epithelium-derived factor (PEDF) [84] and nitric oxide
synthase [85].
Other therapeutics are aimed at inducing cancer
cell apoptosis.TNF-related apoptosis inducing ligand
(TRAIL) is a transmembrane protein that acts via death
receptors to activate the extrinsic apoptotic pathway
resulting in apoptosis of cancer cells without affect-
ing healthy cells. Current chemotherapy agents act via
the intrinsic pathway that senses DNA damage and
again triggers downstream apoptosis. Because there
is cross-talk between the two pathways, combining
TRAIL therapy with chemotherapy results in a syn-
ergistic treatment suggesting thatTRAIL could be used
in conjunction with current first-line clinical thera-
pies [86–88]. Pre-clinical work using MSCs modified
to express different forms ofTRAIL have been shown
to have therapeutic efficacy in pre-clinical models of
mesothelioma [26,72], lung metastases [25], breast
cancer [89], cervical cancer [90], myeloma [91] and
glioma [22]. Another apoptotic protein, apoptin, has
similar properties and has been used against hepato-
cellular carcinoma [92].
Other novel approaches to cancer treatment are
the delivery of suicide genes via MSCs.The premise
behind this therapy is that MSCs engineered to express
suicide genes are delivered into tumors and are acti-
vated once treatment with systemic chemotherapy
agents is given. This approach has been demon-
strated largely in glioma using MSCs expressing
cytosine deaminase/uracil phosphoribosyltransferase
(CDy/UPRT), which is activated after treatment with
5-fluorocytosine (5-FC) [93] and MSCs expressing
thymidine kinase, which is subsequently activated with
ganciclovir [94].
Many of these agents are attractive for delivery via
MSCs because their use as anti-cancer agents after
systemic delivery is limited by short half-lives or ex-
cessive systemic toxicity [95]. For some agents, the
concentrations required to result in a therapeutic effect
would be significantly higher than levels achieved fol-
lowing intravenous systemic administration at a
tolerated dose [96–98]. Enabling delivery of the agent
directly into the tumor would allow long-term low-
dose protein expression without the toxicities seen with
systemic delivery.
Therapies in clinical trials
With so many pre-clinical studies showing the in vitro
efficacy of many types of genetically modified cell
therapy, it is perhaps not surprising that the next step
is assessing the safety and efficacy of these therapies
in the clinical trial setting. Looking at the literature,
there are more than 500 clinical trials looking at the
safety and efficacy of MSCs from either allogeneic or
autologous sources, and there is overwhelming evi-
dence of safety. From an efficacy perspective however
the results have been largely disappointing.The ma-
jority of clinical trials have been in the treatment of
inflammatory conditions such as chronic obstructive
pulmonary disease [4] and adult respiratory distress
Table II. Pre-clinical studies assessing the utility of genetically modified MSCs in cancer.
Tumor type Therapeutic modification Cell type Effects Ref
Breast IFN-β BM-MSC Reduced tumor growth and metastases and prolonged survival [73]
Breast TRAIL BM-MSC Reduced tumor growth and metastases [28,89]
Lung PEDF mBM-MSC Reduced tumor growth and prolonged survival [113]
Lung TRAIL hUC-MSC Prolonged survival and increased tumor apoptosis [114]
Mesothelioma TRAIL hBM-MSC Reduced tumor growth [26]
Glioma CDU hAD-MSC Tumor regression and prolonged survival [93]
Glioma HSV-tK hAD-MSC Reduced tumor growth [94,115]
Glioma TRAIL hUC-MSC Reduced tumor growth [22,116]
Glioma TRAIL hBM-MSC Inhibits tumor growth [21]
HCC Apoptin hBM-MSC Reduced tumor volume [92]
HCC HNF4α hUC-MSC Reduced tumor growth [117]
HCC IFN-β hBM-MSC Decreased tumor formation [118]
HCC HSV-tK mBM-MSC Reduced tumor growth [103]
Pancreas HSV-tK mBM-MSC Reduced tumor growth and metastases [31]
Ascites IL-12 mBM-MSC Reduced ascites volume and prolonged survival [119]
Lymphoma IL-21 mBM-MSC Delayed tumor development and prolonged survival [120]
Prostate IFN-β hBM-MSC Reduced tumor weight and prolonged survival [121]
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syndrome [5,99], but regardless of the disease being
treated, they all use unmodified MSCs for their
immunomodulatory and anti-inflammatory properties.
To date there have been no clinical trials looking
at the delivery of genetically modified MSCs in pa-
tients with cancer; however, this landscape is set to
change with two first-in-human clinical trials assess-
ing genetically modified MSCs in gastrointestinal
cancer and lung cancer.There are a number of chal-
lenges when translating this type of cell therapy into
the clinic, in particular around manufacturing a clinical-
grade product. Cell and gene therapies differ from
traditional biopharmaceuticals in that they are inher-
ently a heterogenous living product, the characteristics
of which can be affected by multiple variables, such
as the culture media, conditions of hypoxia versus
normoxia, adherent versus spheroid culture and any
changes in process that need to be performed to achieve
a large-scale expansion while remaining cost-effective.
To ensure products retain their efficacy, any changes
in conditions require evidence that both the MSC func-
tion and that of the therapeutic protein remain
unaffected. Another of the great unknowns regard-
ing cell therapies is the fate of the cells after intravenous
delivery. It is possible that the clinical trials to date
have shown limited efficacy because the cells are
quickly removed from the body.To highlight the chal-
lenges and rationale behind clinical trial design for these
products, the following sections discuss in more detail
the two ongoing trials using genetically modified cell
therapies for cancer.
TREAT-ME1 trial for gastrointestinal tumors
Adenocarcinomas of the gastrointestinal system account
for significant morbidity and mortality, and, as with
many cancers, treatment is complicated by high rates
of tumor recurrence, resistance to chemotherapies and
the presence of locally advanced disease that is not
amenable to surgical resection [100]. These malig-
nancies share common morphologic characteristics
regardless of the tissue of origin, in particular the pres-
ence of a tumor stromal microenvironment that is
permissive to metastasis formation [101]. Attempts to
target novel cancer treatments to components of the
microenvironment in a bid to suppress tumor growth
and metastases have shown pre-clinical efficacy [102],
and in particular groups have looked to harness the
tumor tropic ability of MSCs to develop new anti-
cancer therapeutics.
Pre-clinical rationale
Once MSCs are recruited to the tumor microenvi-
ronment, they induce the expression of the chemokine
CCL5/RANTES, which causes increased tumor neo-
vascularization and aids the recruitment of other
stromal cell types to encourage tumor growth. Zischek
et al. [31] used this mechanism to design a geneti-
cally modified cell therapy that would be attracted to
the tumor stroma and activated by the presence of
CCL5 to release a suicide gene resulting in tumor cell
death.To achieve this, they stably transfected MSCs
with a retroviral vector expressing thymidine kinase
of the herpes simplex virus (HSV-Tk) under the control
of a CCL5/RANTES promoter and delivered it in-
travenously to an orthotopic pancreatic tumor model.
After cell delivery, animals received the pro-drug
ganciclovir, which is phosphorylated by the HSC-
Tk and drives cells into apoptosis. Delivery of these
genetically modified cells resulted in a reduction in
tumor growth and metastasis formation [31].The same
cells were tested in an orthotopic model of hepato-
cellular carcinoma with a similar therapeutic outcome
[103].
By exploiting the biological activity of the tumor
microenvironment, it has been possible to develop a
genetically modified cell therapy that is only acti-
vated within the tumor deposit in response to the
presence of a selectively expressed chemokine. Acti-
vated cells can then be used to initiate a pro-apoptotic
process resulting in the selective death of cancer cells.
By combining these properties, this novel cancer
therapy should have high efficacy with few side effects.
Clinical trial design
Continuing on from their pre-clinical work,TREAT-
ME 1 is a prospective, uncontrolled, single-arm phase
I/II study to assess the safety and efficacy of autolo-
gous MSCs genetically modified with a retroviral vector
expressing tyrosine kinase and subsequent ganciclovir
infusions in patients with gastrointestinal adenocar-
cinoma [104] that is currently recruiting patients.
In this first-in-human study, the investigating group
has joined with a commercial partner, Apceth, to
develop the investigational medicinal product (IMP)
MSC_apceth_101.This uses autologous BM-MSCs
that are isolated and expanded to passage 1 and sub-
sequently transduced using a gamma-retroviral SIN-
vector to express HSV-Tk under the control of the
RANTES promoter.To ensure a pure population after
transduction, cells are selected using puromycin and
then expanded to generate the clinically required dose
before being cryopreserved.To release the IMP, certain
criteria need to be met, and these should reflect the
safety and efficacy of the product. For this product,
>90% of cells should express MSC markers and cell
viability should be >80% with >75% of cells positive
for the transgene and evidence of adequate transgene
expression as determined by the sensitivity to ganciclovir.
When considering standard clinical trial design,
most phase I studies are dose-escalation studies, and
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this trial is no different. Patients will receive three IMP
infusions dosed according to body weight 1 week apart
followed by ganciclovir given on 3 consecutive days
starting 48–72 h after IMP delivery. Two doses will
be tested, 0.5 × 106 and 1 × 106 cells/kg per dose. As-
suming no dose-limiting side effects, the study will
proceed to phase II. Phase II will treat 16 patients with
adenocarcinoma of the gastrointestinal tract who will
be divided into two groups: relapse/progression of
disease or patients eligible for neoadjuvant therapy
before surgery in which the IMP will be delivery 48–
72 h before surgery as a single dose and ganciclovir
on days 1–3 post-operatively.The primary end point
of the trial is safety and tolerability of the IMP with
secondary end points of tumor size and total number
of metastases by Response Evaluation Criteria In Solid
Tumors (RECIST) criteria. Additional information re-
garding the localization of the MSCs after delivery will
be collected using the group of patients who will receive
the IMP therapy immediately pre-operatively because
this will enable detection of the therapeutic transgene
in both resected tumor samples but also normal tissue
adjacent to the tumor. This will start to provide key
information to help address some of the unknowns
regarding cell and gene therapy, in particular loca-
tion and evidence of therapeutic gene expression and
the results will be eagerly awaited.
TACTICAL trial for lung cancer
Pre-clinical rationale
Lung cancer is the leading cause of cancer death world-
wide, and about 80% of lung cancer patients have a
non–small cell histological subtype. Although early
disease can be surgically resected with a curative
outcome, the majority of patients present with ad-
vanced incurable disease [105]. For this patient
population, chemotherapy with cisplatin and pemetrexed
offers a survival benefit over active symptom control,
but this benefit is small with an increase in median sur-
vival of 1.5 months [106].
One of the key benefits of using MSCs is to harness
their tumor tropic effect to enable targeted delivery
of anti-cancer therapies.TRAIL is an attractive cancer
therapeutic because it selectively induces apoptosis in
cancer cells without affecting healthy cells, although
the precise mechanism through which this occurs is
not clearly defined.TRAIL works by activating the ex-
trinsic apoptotic pathway by binding to cell surface
death receptors, whereas existing chemotherapies
trigger the intrinsic apoptotic pathway by causing DNA
damage. Because there is significant crosstalk between
these two pathways, there is the potential of a syner-
gistic effect of TRAIL with existing chemotherapy
agents [87,107]. In pre-clinical work, we have shown
that MSCs can be successfully transduced with a
lentiviral vector expressing TRAIL with transduc-
tion efficiencies of great than 90%. These TRAIL
transduced MSCs can home to tumors and induce
apoptosis, resulting in a reduction in tumor growth
in both a lung metastases and mesothelioma model
[25,26].
Clinical trial design
To follow on from this work, we are in the process of
setting up theTACTICAL (TArgeted stem Cells ex-
pressing TRAIL as a therapy for lung CAncer) trial.
This is a multicenter, prospective, randomized phase
I/II trial to assess the safety and efficacy of third-
party allogeneic MSCs transduced to expressTRAIL
as a first-line therapy in conjunction with chemother-
apy in patients with metastatic adenocarcinoma of the
lung. Currently the product is undergoing manufac-
ture according to Good Manufacturing Practice
criteria, and this has highlighted some of the chal-
lenges faced when manufacturing this kind of therapy
at large scale.
Cell manufacture and release
Although MSCs are easy to isolate and expand in vitro
reaching up to 50 population doublings, to ensure
maximum efficacy and safety in the clinical setting,
this figure is kept below 20 [108].The majority of clin-
ical trials using unmodified MSCs have used in the
range of 1 × 106 to 5 × 106/kg and often use multiple
doses, meaning the number of cells required per patient
can reach as high as 108. To produce the number of
cells required and remain cost-effective, the best way
to meet demand is to manufacture a master cell bank
(MCB) of allogeneic cells that can be cryopreserved
and expanded as required to make a working cell bank
(WCB).This is the approach theTACTICAL trial is
taking, and both to ensure maximum production ca-
pacity and to reduce the impact of the inherent
variability of MSCs, we are pooling cells from mul-
tiple donors before transduction (Figure 1).
Both the MCB andWCB will be cryopreserved so
that samples can be taken for stability assays and release
criteria. Although most of the clinical trials using al-
logeneic MSCs have thawed the therapeutic product
at the bedside, there has been some discussion in the
literature that cryopreservation can affect certain key
therapeutic characteristics of the cell product.We have
already modified our cryopreservation procedure to
ensure that our product is not affected, but this should
be checked for any cell and gene therapy product that
requires freezing [109].
To be fully compliant with the regulatory require-
ments set out by the European Medicine Agency,
release criteria must be established and confirmed on
both the MCB andWCB.These criteria are based not
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only on the basic characteristics required to confirm
the MSC identification, viability, and sterility but also
those required to ensure that the product demon-
strates its potency and efficacy for its intended clinical
application. This can be particularly challenging for
untransduced MSCs whose mode of action is not
always clearly defined and to attempt to address this
and create a gold standard, the International Society
for Cellular Therapy has recently published guide-
lines on standardized immune functional assays to
demonstrate MSC potency [110].This is an area where
modified MSCs have an advantage in that the gene
modification is usually what determines therapeutic
potency and is often a much more objective readout.
Cell localization
Another great uncertainty regarding MSC therapy is
the fate of the cells after intravenous injection. Al-
though there is a wealth of pre-clinical data using a
wide variety of optical imaging techniques, to date there
are limited data from human studies. Again, one of
the challenges for unmodified MSCs is how to iden-
tify cells once they have been delivered systemically
when there is no idea of location or duration within
the recipient tissue; however, when the cells carry a
genetic modification then location of small numbers
of donor cells within recipient tissues can be more
straightforward. There is also a head start when it
comes to location of the cells because of the tumor
tropism they show.
TheTREAT-ME1 trial is attempting to add human
data to the literature by delivering modified MSCs to
patients after chemotherapy but before surgical re-
section. Cells will be administered within 72 h of
surgery, and samples taken will be analyzed for the
presence of the transgene, the activation of the
transgene promoter or the transcription of the ther-
apeutic gene. In addition, they will assess for other
surrogate markers including tumor neo-angiogenesis,
co-localization of modified cells within the tumor site
and surrounding tissues and assessment of the tumor
microenvironment [104].
In the TACTICAL trial, we are using an image-
based approach looking at novel radioisotope labeling
that can be detected using positron emission tomog-
raphy (PET) to enable us to visualize MSCs over
multiple time periods. Indium-111 (111In) is already
routinely used in the clinical setting for white cell and
eosinophil labeling and has been assessed as a label-
ing agent for MSCs. Although MSCs can be labeled
successfully with 111In, they have low labeling effi-
ciency at approximately 25%, retention within the cells
overtime is low and it is more toxic to the cells than
it is to leucocytes [111,112]. In addition, the 111In is
detected using single-photon emission computed to-
mography (SPECT) imaging, which does not give as
good spatial resolution as tracers that are detected by
positron emission tomography scanning.We are cur-
rently validating a novel radioisotope and assessing it
as a suitable clinical alternative to 111In labeling and
SPECT imaging. If this agent proceeds to use in the
clinical trial, the information gained will further inform
future dosing schedules and help to identify any pos-
sible off-target effects that would direct potential
additional safety monitoring. In addition to the lon-
gitudinal imaging, we also propose to collect post
mortem samples on patients who give appropriate
consent to identify the presence of our allogeneic modi-
fied MSCs in tumor samples and to assess both tumor
proliferation and apoptosis.
Summary
Cancer is a devastating disease, and despite some sig-
nificant advances in cancer therapy, patients who
present with advanced, metastatic disease have limited
treatment options. Pre-clinical studies using geneti-
cally modified stem cells frommultiple sources carrying
a wide array of therapeutic proteins have shown great
promise in the treatment of cancer and have made the
progression to first-in-human studies almost inevitable.
Even with the ability to build on the great founda-
tions provided by the many clinical trials using
unmodified MSCs, the delivery of a genetically modi-
fied cell therapy trial remains a significant challenge.
The manufacturing process is still one of the great-
est barriers to clinical use, and to remain relatively cost-
effective, a simple, streamlined process needs to be
developed. Although the use of autologous cells un-
doubtedly has its benefits, the ability to have a
cryopreserved allogeneic modified cell therapy will help
reduce the inherent stress and costs of manufacturing;
Transduction
Donor 1
Isolation
Donor 2
Isolation
Donor 3
Isolation
P1 MSC P1 MSC P1 MSC
P1
Pooled
P2
MSCTRAIL
MCB
Figure 1. Schematic diagram showing the proposed manufactur-
ing outline of theTACTICAL trial.MSCTRAIL,TRAIL-transduced
MSCs.
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to date there is no evidence of immune rejection of
this type of product.The knowledge generated from
the first two novel clinical trials assessing cell and gene
therapy products in patients with cancer will hope-
fully inform further trials and help to progress this
rapidly expanding field and offer great hope for pa-
tients with few options.
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